Key Takeaways
- BMS needs sales growth to offset upcoming losses of exclusivity for Opdivo and Eliquis – more than half of its Q1 2025 revenue – and calls are increasing for the company to do more deals.
- CEO Christopher Boerner said business development is a top priority for Bristol’s capital allocation and it is looking to execute both acquisitions and partnerships across its five therapeutic areas.
- R&D setbacks and below consensus sales for the growth portfolio underlie the need for BMS to buy more growth through BD, especially with key new molecular entity readouts not due until 2026.
Bristol Myers Squibb is three years away from facing generic and biosimilar competitors for its two top-selling products – Eliquis (apixaban) and Opdivo (nivolumab), which delivered 52% of the company’s...
BMS CEO Christopher Boerner faced just as many questions on 24 April during the company’s Q1 earnings call about the impact of tariffs, drug pricing and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?